Global Blood Therapeutics, Inc (GBT)

Etorro trading 970x250
Global Blood Therapeutics, Inc (GBT) Logo

About Global Blood Therapeutics, Inc

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California. Address: 181 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Global Blood Therapeutics, Inc News and around…

Latest news about Global Blood Therapeutics, Inc (GBT) common stock and company :

GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
12 May, 2022 Yahoo! Finance

New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an

Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week
11 May, 2022 Yahoo! Finance

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Why Global Blood Therapeutics Stock Was Sickly Today
05 May, 2022 FinancialContent

The bears pounced on the company despite a first-quarter bottom-line beat.

GBT Announces Participation in Upcoming Investor Conferences
05 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor conferences: Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, at 2:40 p.m. P.T.; andRBC Capital Markets 2022 Global Healthcare Conference in New York, NY on Wednesday, May 18, at 9:00 a.m. E.T. The fireside chats will be webcast live from GBT’s website at w

GBT Announces New Employment Inducement Grants
05 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2022, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 46,400 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employe

Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
05 May, 2022 Yahoo! Finance

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript
05 May, 2022 FinancialContent

GBT earnings call for the period ending March 31, 2022.

Recap: Global Blood Therapeutics Q1 Earnings
04 May, 2022 FinancialContent

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors ...

Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
04 May, 2022 Yahoo! Finance

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GBT Reports First Quarter 2022 Financial Results
04 May, 2022 Yahoo! Finance

Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 years and over Reinitiated GBT601 Phase 1 trial in sickle cell disease (SCD) patients to study 150 mg daily dose; on track to initiate Phase 2/3 trial by mid-year Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 20

GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
28 Apr, 2022 Yahoo! Finance

Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate GovernanceSOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environmental, social and governance (ESG) report, which

Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
27 Apr, 2022 Yahoo! Finance

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
27 Apr, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201

Looking Into Global Blood Therapeutics's Return On Capital Employed
26 Apr, 2022 FinancialContent

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. ...

A Look At The Intrinsic Value Of BMTC Group Inc. (TSE:GBT)
11 Apr, 2022 Yahoo! Finance

How far off is BMTC Group Inc. ( TSE:GBT ) from its intrinsic value? Using the most recent financial data, we'll take a...

BMTC GROUP INC. ANNOUNCES THE RENEWAL OF ITS NORMAL COURSE ISSUER BID TO ACQUIRE COMMON SHARES
08 Apr, 2022 Yahoo! Finance

(TSX: GBT) The Company announces that it has received the required regulatory approvals to renew its normal course issuer bid to acquire for cancellation Common Shares listed on the Toronto Stock Exchange (the "TSX") for the period between April 15th, 2022 and April 14th, 2023, at the latest. The Company's previous normal course issuer bid ends April 14th, 2022. Pursuant to its renewed normal course issuer bid, the Company intends to acquire, through the facilities of the TSX and through alterna

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel
06 Apr, 2022 Yahoo! Finance

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel Villepinte, April 6, 2022 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and medical imaging solutions, has announced the appointment of Charlotte Bamière, General Counsel, to the Executive Committee. Charlotte Bamière has contributed to the development of Guerbet’s legal function since joining the Group in 2011. In 2015, Charlotte Bamière and her team played a crucial par

3 “Strong Buy” Stocks to Watch as 2Q22 Kicks Off
04 Apr, 2022 Yahoo! Finance

Last year was marked by strong GDP and corporate earnings growth as the economy reopened and the workforce got back to work post-lockdowns. Stocks rose, too, reaching record highs by year’s end. That all crashed to a halt this past January. This year got started with a steady drop across the main equities indexes, especially on the tech-heavy NASDAQ. The markets troughed, deep in correction territory, in mid-March. Since then they have rebounded, and the stock market losses have moderated. Year-

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA
29 Mar, 2022 Yahoo! Finance

Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based co

Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022
29 Mar, 2022 Yahoo! Finance

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA Priority Review granted by US-FDAMarch 28, 2022 Villepinte (France), March 29 2022 – Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administ

Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
25 Mar, 2022 Yahoo! Finance

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
24 Mar, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T. The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event. About Global Blood Therapeu

What 4 Analyst Ratings Have To Say About Global Blood Therapeutics
28 Feb, 2022 FinancialContent

Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Global Blood Therapeutics (GBT) Q4 2021 Earnings Call Transcript
24 Feb, 2022 FinancialContent

GBT earnings call for the period ending December 31, 2021.

Recap: Global Blood Therapeutics Q4 Earnings
23 Feb, 2022 FinancialContent

Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what ...

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
23 Feb, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD ...

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
20 Feb, 2022 FinancialContent

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and ...

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
16 Feb, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront ...

Add Up The Parts: FYX Could Be Worth $113
10 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Core AlphaDEX Fund ETF (FYX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.52 per unit.

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
02 Feb, 2022 FinancialContent

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the ...

Global Blood Therapeutics, Inc (GBT) is a NASDAQ Common Stock listed in , ,

970x250